This is what I remember from the presentation at the PAN Forum:

At the Emerging Therapies session at the PAN Forum, Dr. Howard Federoff spoke about research on AAV2 virus delivery of GDNF. This was the viral delivery method used in the phase II Ceregene trial. He said it would involve "Convection Enhanced Delivery" (method used in the phase I infused GDNF Un. of Kentucky trials, but not in Amgen's) It gets the GDNF into the brain more efficiently. Also said additional areas of the brain would be targeted. A NINDS consortium has been researchiing viral vector delivery of GDNF in animal models and will be conducting a phase I clinical trial, possibly in Fall 2009. Hopefully more details will be coming....